How to Get Jardiance in Minnesota

What Is Empagliflozin and Why Do Minnesota Clinicians Prescribe It?

Empagliflozin is an SGLT2 inhibitor approved by the FDA for three distinct indications: glycemic control in type 2 diabetes, reduction of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, and risk reduction for heart failure hospitalization and CKD progression. The drug blocks sodium-glucose cotransporter-2 in the proximal renal tubule, causing roughly 60 to 90 grams of glucose to be excreted in the urine each day, which lowers both blood sugar and blood pressure without requiring insulin secretion [1].

EMPA-REG OUTCOME, published in the New England Journal of Medicine in 2015 (N=7,020), showed that empagliflozin reduced the rate of death from cardiovascular causes by 38% relative to placebo (2.7% vs. 4.4% annually, P<0.001) in adults with type 2 diabetes and high cardiovascular risk [2]. That signal changed prescribing patterns across the United States, including Minnesota, where cardiovascular disease is the leading cause of death [3].

The EMPEROR-Reduced trial (N=3,730) extended the evidence to heart failure with reduced ejection fraction. Empagliflozin cut the composite of cardiovascular death or heart failure hospitalization by 25% relative to placebo (HR 0.75 to 95% CI 0.65 to 0.86, P<0.001) [4]. The EMPEROR-Preserved trial (N=5,988) then confirmed benefit in heart failure with preserved ejection fraction, making empagliflozin the first SGLT2 inhibitor with FDA approval across the full ejection-fraction spectrum [5].

For chronic kidney disease, the EMPA-KIDNEY trial (N=6,609) showed a 28% relative risk reduction in the composite of kidney disease progression or cardiovascular death compared with placebo (HR 0.72 to 95% CI 0.64 to 0.82, P<0.001) [6].

How to Get a Jardiance Prescription in Minnesota

Getting a Jardiance prescription in Minnesota requires a licensed prescriber who can evaluate your diagnosis, review contraindications, and send an electronic prescription to a pharmacy. Minnesota law does not restrict which licensed prescribers can write for empagliflozin, so MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) can all prescribe it.

Your first appointment will cover your diagnosis (type 2 diabetes, heart failure, or CKD), a medication history, and a brief cardiovascular risk assessment. The FDA label for empagliflozin specifies that the drug is contraindicated in patients with an eGFR <30 mL/min/1.73 m² for the diabetes indication, though the CKD indication uses a lower threshold and the prescriber will interpret your labs accordingly [1]. The prescriber sends an electronic prescription directly to your chosen Minnesota pharmacy. Most retail chains in the state carry both the 10 mg and 25 mg tablets.

The American Diabetes Association 2024 Standards of Care recommend SGLT2 inhibitors "for patients with type 2 diabetes and established cardiovascular disease, heart failure, or chronic kidney disease to reduce cardiovascular and kidney risk" [7]. That guideline, combined with Minnesota's high prevalence of heart failure, means primary care physicians in the state are increasingly comfortable initiating empagliflozin without referral to an endocrinologist.

Telehealth Prescribing of Jardiance in Minnesota

Telehealth providers licensed in Minnesota can legally prescribe empagliflozin after a synchronous audio-video consultation that satisfies the state's standard-of-care requirements. Minnesota Statutes § 147.37 defines telehealth as "the delivery of health care services or consultations using telecommunications technology" and requires that the prescriber establish a valid patient-provider relationship, which a video visit accomplishes when the provider reviews your medical history and current labs [8].

HealthRX clinicians complete a structured intake that includes chart review, lab evaluation, and a live video visit before sending any prescription. Because empagliflozin is not a controlled substance, no in-person visit is required under either federal DEA rules or Minnesota Board of Medical Practice guidelines [9].

The HealthRX telehealth prescribing pathway for empagliflozin in Minnesota follows four steps:

1. Online intake form (15 minutes): Medical history, current medications, and chief complaint.
2. Lab upload: You submit recent eGFR, creatinine, and urine albumin-creatinine ratio results, or order them through a partnered Minnesota draw site.
3. Video visit (20 to 30 minutes): A Minnesota-licensed MD, NP, or PA reviews your case, confirms the indication, and discusses risks and benefits.
4. Electronic prescription: Sent the same day to your preferred Minnesota pharmacy or shipped from a partnered mail-order pharmacy.

Most patients complete steps one through three on the same day and receive their prescription within 24 hours of the video visit.

Labs Required Before Starting Jardiance in Minnesota

Your prescriber will need at least three laboratory values before initiating empagliflozin, regardless of whether the visit is in-person or via telehealth.

Estimated glomerular filtration rate (eGFR) and serum creatinine. The FDA-approved label restricts use for glycemic control to patients with an eGFR of 45 mL/min/1.73 m² or higher, while the CKD indication is approved down to an eGFR of 20 mL/min/1.73 m² [1]. A baseline creatinine also gives the clinician a reference point for monitoring. The National Kidney Foundation's KDIGO 2022 guideline recommends SGLT2 inhibitors for CKD patients with an eGFR of 20 to 45 mL/min/1.73 m² and urinary albumin excretion above 200 mg/g [10].

Urinary albumin-creatinine ratio (UACR). This value quantifies kidney damage and helps confirm the CKD indication. KDIGO 2022 defines high-risk CKD as a UACR above 300 mg/g [10].

HbA1c (if prescribing for type 2 diabetes). A baseline HbA1c documents glycemic status and allows the prescriber to track response at the 3-month follow-up visit. The ADA 2024 Standards of Care target an HbA1c below 7% for most non-pregnant adults with type 2 diabetes, though individualized goals are common [7].

A basic metabolic panel, complete blood count, and blood pressure measurement round out the typical pre-prescription workup. Minnesota draw sites that partner with telehealth platforms include LabCorp and Quest Diagnostics locations across the Twin Cities, Duluth, Rochester, and St. Cloud corridors.

Minnesota Medicaid (Medical Assistance) Coverage and Prior Authorization

Minnesota Medical Assistance covers Jardiance with prior authorization for three indications: type 2 diabetes, heart failure with reduced ejection fraction (HFrEF), and chronic kidney disease. The Minnesota Department of Human Services Preferred Drug List places empagliflozin in a tier that requires PA before dispensing [11].

A typical PA submission includes the patient's ICD-10 diagnosis code, documentation that first-line agents were tried (metformin for T2D, or evidence of guideline-directed medical therapy for HF or CKD), recent lab values (HbA1c for T2D or eGFR for CKD and HF), and the prescriber's attestation of cardiovascular or renal risk. PA decisions from Minnesota Medical Assistance are generally returned within three business days for standard requests or 24 hours for urgent requests [11].

Commercial insurers in Minnesota, including UCare, HealthPartners, Blue Cross Blue Shield of Minnesota, and Medica, each maintain their own formulary tiers for empagliflozin. Most place brand-name Jardiance on tier 3 or tier 4, with copays ranging from $45 to $150 per 30-day supply after deductible. The Lilly Insulin Value Program and Boehringer Ingelheim's Jardiance Savings Card can reduce out-of-pocket costs to as low as $10 per month for eligible commercially insured patients [12].

Patients without insurance can use GoodRx or similar discount programs. As of early 2025, GoodRx prices for a 30-tablet supply of Jardiance 10 mg at Minnesota pharmacies range from approximately $480 to $540, varying by location and chain [13].

503A Pharmacy Access for Empagliflozin in Minnesota

Minnesota-licensed 503A compounding pharmacies may prepare custom formulations of empagliflozin, such as suspensions for patients with swallowing difficulties or non-standard doses for specific clinical protocols. A 503A pharmacy compounds medications on a patient-specific basis following a valid prescription, unlike a 503B outsourcing facility, which produces large batches for healthcare facilities [14].

The Minnesota Board of Pharmacy licenses and inspects 503A pharmacies under Minnesota Statutes § 151.01. Compounded empagliflozin preparations are not FDA-approved finished drug products, so the prescriber must document a specific patient need that justifies compounding rather than dispensing the commercially available tablet [15].

Telehealth prescribers can legally send a compounded empagliflozin prescription to a Minnesota-licensed 503A pharmacy provided the pharmacy holds an active non-resident or in-state license and the prescription meets all state requirements. The compound is then shipped directly to the patient.

Transferring an Existing Jardiance Prescription to Minnesota

Patients relocating to Minnesota from another state can transfer an active Jardiance prescription to a Minnesota pharmacy, provided the prescription has refills remaining and was issued by a licensed prescriber. Minnesota pharmacy law (Minn. Stat. § 151.102) allows pharmacies to accept prescription transfers from out-of-state pharmacies for non-controlled drugs [16].

If your original prescription has expired or has no refills remaining, you will need a new prescription from a Minnesota-licensed prescriber. A telehealth provider can often issue that renewal prescription the same day as your intake visit, avoiding a gap in therapy. The American Heart Association has noted that gaps in SGLT2 inhibitor therapy in heart failure patients may increase the short-term risk of hospitalization, which underscores the importance of continuous access [17].

Monitoring After Starting Empagliflozin in Minnesota

After the first fill, most guidelines recommend a follow-up visit at four to twelve weeks to assess tolerability, blood pressure changes, and repeat eGFR. The FDA label notes that a modest initial decline in eGFR (roughly 2 to 5 mL/min/1.73 m² in the first weeks) is expected and does not indicate drug-induced nephrotoxicity; it reflects the drug's hemodynamic effect on glomerular pressure [1].

The KDIGO 2022 guideline advises retesting eGFR and UACR at three months after initiation and then annually in stable patients [10]. HbA1c should be checked every three months until target is reached, then every six months in stable patients per ADA 2024 [7].

Genital mycotic infections occur in roughly 5 to 10% of patients in clinical trials and are the most common adverse effect requiring attention [2]. Diabetic ketoacidosis, though rare with empagliflozin (incidence below 0.1% in EMPA-REG OUTCOME), is a serious risk in patients who are fasting, dehydrated, or undergoing surgery; Minnesota prescribers typically advise holding the drug 48 to 72 hours before elective procedures [2].

Blood pressure should be re-measured at every follow-up. EMPA-REG OUTCOME showed a mean systolic blood pressure reduction of 4 mmHg from baseline with empagliflozin 10 mg, which can be clinically significant in patients already on antihypertensives [2]. Dose adjustment of concurrent antihypertensives may be needed.

Dosing and Administration

The standard starting dose for all three FDA-approved indications is empagliflozin 10 mg orally once daily in the morning, with or without food [1]. For additional glycemic control in type 2 diabetes, the prescriber may increase to 25 mg once daily after four weeks if the patient tolerates the 10 mg dose.

The 25 mg dose has not been shown to provide additional cardiovascular or renal protection beyond the 10 mg dose in major outcome trials, so many cardiologists and nephrologists maintain patients at 10 mg unless glycemic control is the primary treatment goal [4]. The FDA label does not require dose adjustment for hepatic impairment but does limit or contraindicate use in severe renal impairment as noted above [1].

Empagliflozin can be combined with metformin, GLP-1 receptor agonists (such as semaglutide or liraglutide), insulin, sulfonylureas, and DPP-4 inhibitors. Combination with a GLP-1 RA and an SGLT2 inhibitor is increasingly supported by guideline documents for patients with both high cardiovascular risk and suboptimal glycemic control [7].

Cost and Savings Programs for Minnesota Patients

Brand-name Jardiance carries a list price of approximately $600 to $650 for a 30-tablet supply as of 2025. Several programs reduce this cost substantially for Minnesota patients.

The Jardiance Savings Card from Boehringer Ingelheim and Lilly offers eligible commercially insured patients a copay of as low as $10 per month, capped at a defined annual maximum [12]. Patients on Medicare Part D are not eligible for this card under federal law, but the Inflation Reduction Act's $2,000 out-of-pocket cap for Part D beneficiaries beginning in 2025 significantly reduces the annual burden for Medicare patients [18].

Minnesota's pharmaceutical assistance program, Minnesota Rx Connect, provides additional support for residents who do not qualify for Medical Assistance but cannot afford private drug costs. The program connects patients with manufacturer patient-assistance programs, including Boehringer Ingelheim's patient-assistance program for Jardiance, which may supply the drug free of charge to qualifying low-income patients [19].

The VA/DoD Clinical Practice Guideline for Diabetes Management (2023 update) covers empagliflozin for eligible Minnesota veterans receiving care through the Minneapolis VA Health Care System or other regional VA facilities, typically at low or no cost to the patient [20].